Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1997-02-10
2004-11-02
Saoud, Christine J. (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S243000, C435S320100, C435S071100, C435S325000, C530S351000, C536S023500
Reexamination Certificate
active
06812004
ABSTRACT:
FIELD OF THE INVENTION
The present invention is directed to compositions related to proteins which function in controlling development and differentiation of mammalian cells, e.g., cells of a mammalian immune system. In particular, it provides proteins and mimetics, and antibodies which regulate development, differentiation, and function of various cell types, including hematopoietic cells.
BACKGROUND OF THE INVENTION
The circulating component of the mammalian circulatory system comprises various cell types, including red and white blood cells of the myeloid, lymphoid, megakaryotoid, or the erythroid cell lineages. See, e.g., Rapaport (1987)
Introduction to Hematology
(2d ed.) Lippincott, Philadelphia, Pa.; Jandl (1987)
Blood: Textbook of Hematology
, Little, Brown and Co., Boston, Mass.; and Paul (ed. 1993)
Fundamental Immunology
3d ed., Raven Press, N.Y. Progression through various stages of differentiation are regulated by various signals provided to the cells, often mediated through a class of soluble proteins known as the cytokines. Within this class of molecules is a group known as the chemoattractant cytokines, or chemokines. See, e.g., Schall (1994) “The Chemokines” in
The Cytokine Handbook
(2d ed.) Academic Press; Schall and Bacon (1994)
Current Opinion in Immunology
6:865-873.
Although the chemokines have not been tested over the full spectrum of biological activities, the best described biological functions of these molecules relate to chemoattraction of leukocytes. However, new chemokine-like molecules are being discovered, and their biological effects on the various cells responsible for immunological responses are topics of continued study.
Many observations indicate that other factors exist whose functions in hematopoiesis, immune development, and leukocyte trafficking are heretofore unrecognized. These factors provide possible biological activities whose spectra of effects are distinct from known differentiation, activation, or other signaling factors. Moreover, new biological activities of chemokine-like molecules on other cell types have yet to be discovered. The absence of knowledge about the structural, biological, and physiological properties of the regulatory factors which regulate, e.g., hematopoietic cell physiology in vivo, prevents the modification of the effects of such factors. Thus, medical conditions where regulation of the development or physiology of relevant cells is required remain unmanageable.
SUMMARY OF THE INVENTION
The present invention is based, in part, upon the discovery of new genes, designated dendrokines, encoding members of the class of CC chemokines. These dendrokines appear to be specifically expressed in dendritic cells. It embraces agonists and antagonists of the dendrokines, e.g., mutations (muteins) of the natural sequences, fusion proteins, chemical mimetics, antibodies, and other structural or functional analogs. It is also directed to isolated genes encoding proteins of the invention. Various uses of these different protein or nucleic acid compositions are also provided.
The present invention provides a substantially pure dendrokine; a fusion protein comprising dendrokine sequence; an antibody or antigen binding fragment thereof which exhibits specificity of binding to a dendrokine; and a nucleic acid encoding a dendrokine or fusion protein thereof.
In dendrokine embodiments, the chemokine may comprise a mature dendrokine sequence of Table 1; have a natural sequence; exhibit a post-translational modification pattern distinct from natural dendrokine; be 3-fold or fewer substituted from a natural sequence; be detectably labeled; be attached to a solid substrate; or be denatured. The invention also embraces a sterile composition comprising the dendrokine. The dendrokine composition may also attract a cell of hematopoietic origin.
In fusion protein embodiments, the protein may comprise either sequence of Table 1; and/or sequence of another cytokine or chemokine.
In antibody embodiments, the dendrokine can be a human protein or denatured; or the antibody may be raised against a peptide sequence of Table 1 or a purified primate dendrokine; may be a monoclonal antibody; be from a rabbit or mouse; be detectably labeled; be attached to a solid substrate; or bind to said dendrokine with a Kd of at least about 300 &mgr;M. Binding fragments of the antibodies can be an Fv fragment, an Fab fragment, or an F(ab)2 fragment; be fused to another protein segment; or be coupled to another chemical moiety.
The invention further provides methods of making a dendrokine-antibody complex by contacting a primate dendrokine to a binding antibody; and may further allow purification of the dendrokine or antibody.
In nucleic acid embodiments, the chemokine may be from a primate, including a human, or have a naturally occurring sequence. The nucleic acid may have a natural sequence; hybridize at 65° C. and 50 mM salt to the coding sequence of Table 1; comprise a coding sequence of Table 1; be detectably labeled; be an expression vector; be operably associated with a regulatory or control sequence; be at least about 330 nucleotides in length; be a PCR product, or comprise a deoxyribonucleic acid nucleotide. The invention also provides a method of making a chemokine protein comprising a step of expressing such a nucleic acid.
The invention also provides a kit comprising: a substantially pure dendrokine, or fragment thereof; an antibody which binds with specificity to a mammalian dendrokine; or a nucleic acid encoding a dendrokine or peptide of about 17 amino acids. The kit may also be capable of making a qualitative or quantitative analysis.
In another embodiment, the invention provides methods of modulating physiology or development of a cell comprising contacting the cell with an agonist or antagonist of a mammalian dendrokine. The antagonist may be an antibody against a mammalian dendrokine and result in the regulation of autoimmunity, tissue rejection, or an undesired response to an antigen. In embodiments encompassing an agonist, the modulating can result in the regulation of an infectious disease, a vaccine response, or a cancer.
REFERENCES:
patent: WO97/07198 (1997-02-01), None
patent: WO97/11969 (1997-04-01), None
Sara et al., IDC 271 (35) Aug. 1996, p. 21514.*
Imai et al Genbank Submission 1994, Accession No D43767.*
Adena et al,Nature387, 1997, p. 713.*
Hishoma et al,J. Immonul159, 1997, p. 1140 (abst only).*
Vicuri et al,Immunity7(2) 1997, p. 271 (abst only).*
ZlstnikJ. Immunol157, 1996 p. 2726.*
Warren et al,9thInternational Cong. Immunol, 1995, #109.*
Derwent Geneseq Patent Sequence Database, Accession No. 97P-W22889, citing: WO 9729192 A1, date Aug. 14, 1997; WO97-US1248, date Feb. 7, 1997; US 96-600114, date Feb. 12, 1996. “Search record pertaining to human Dendrokine, performed on Jul. 7, 1998”.
Derwent Geneseq Patent Sequence Database, Accession No. 97P-W14917, citing: WO9711969 A1, date Apr. 3, 1997; WO 96-JP2801, date Sep. 27 1996; JP 96-56044, date Mar. 13, 1996; JP 95-249457, date Sep. 27, 1995. “Search record pertaining to human Dendrokine, performed on Jul. 7, 1998”.
Derwent Geneseq Patent Sequence Database, Accession No. 97P-W14918, citing: WO 9711969 A1, date Apr. 3, 1997; WO 96-JP2801, date Sep. 27, 1996; JP 96-56044, date Mar. 13, 1996; JP 95-249457, date Sep. 27, 1995. “Search record pertaining to human Dendrokine, performed on Jul. 7, 1998”.
Derwent Geneseq Patent Sequence Database, Accession No. 97P-W38171, citing: WO 9741230 A1, date Nov. 6, 1997; WO 97-EP2217, date Apr. 30, 1997; DE 96-19617312, date Apr. 30, 1996. “Search record pertaining to human Dendrokine, performed on Jul. 7, 1998”.
Derwent Geneseq Patent Sequence Database, Accession No. 96P-R95691, citing: WO 9616979 A1, date Jun. 6, 1996: WO 95-US15484, date Nov. 29, 1995: US 94-347492, date Sep. 27, 1995. “Search record pertaining to human Dendrokine, performed on Jul. 7, 1998”.
Zhugong Liu, et al.,Chem. Abstracts, 121(19):869, Abstr. 228443z, 1994. “Cytokine production by MTSC 4 cells, an established mouse thymic dendritic cell line”.
Mansour Moham
Banchereau Jacques
Caux Christophe
Lebecque Serge J. E.
Biro Michael G.
Saoud Christine J.
Schering Corporation
Thampoe Immac J.
LandOfFree
Mammalian dendritic cell chemokine reagents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian dendritic cell chemokine reagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian dendritic cell chemokine reagents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3354126